Yael Shani

Differential T cell response in central and peripheral nerve injury: connection with immune privilege

The central nervous system (CNS), unlike the peripheral nervous system (PNS), is an immune‐privileged site in which local immune responses are restricted. Whereas immune privilege in the intact CNS has been studied intensively, little is known about its effects after trauma. In this study, we examined the influence of CNS immune privilege on T cell response to central nerve injury. Immunocytochemistry revealed a significantly greater accumulation of endogenous T cells in the injured rat sciatic nerve than in the injured rat optic nerve (representing PNS and CNS white matter trauma, respectively). Use of the in situ terminal deoxytransferase‐catalyzed DNA nick end labeling (TUNEL) procedure revealed extensive death of accumulating T cells in injured CNS nerves as well as in CNS nerves of rats with acute experimental autoimmune encephalomyelitis, but not in injured PNS nerves. Although Fas ligand (FasL) protein was expressed in white matter tissue of both systems, it was more pronounced in the CNS. Expression of major histocompatibility complex (MHC) class II antigens was found to be constitutive in the PNS, but in the CNS was induced only after injury. Our findings suggest that the T cell response to central nerve injury is restricted by the reduced expression of MHC class II antigens, the pronounced FasL expression, and the elimination of infiltrating lymphocytes through cell death.—Moalem, G., Monsonego, A., Shani, Y., Cohen, I. R., Schwartz, M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J. 13, 1207–1217 (1999)

Dopamine, through the Extracellular Signal-Regulated Kinase Pathway, Downregulates CD4+CD25+ Regulatory T-Cell Activity: Implications for Neurodegeneration

Fighting off neuronal degeneration requires a well controlled T-cell response against self-antigens residing in sites of the CNS damage. The ability to evoke this response is normally suppressed by naturally occurring CD4+CD25+ regulatory T-cells (Treg). No physiological compound that controls Treg activity has yet been identified. Here, we show that dopamine, acting via type 1 dopamine receptors (found here to be preferentially expressed by Treg), reduces the suppressive activity and the adhesive and migratory abilities of Treg. Treg activity was correlated with activation of the ERK1/2 (extracellular signal-regulated kinase 1/2) signaling pathway. Systemic injection of dopamine or an agonist of its type 1 receptors significantly enhanced, via a T-cell-dependent mechanism, protection against neuronal death after CNS mechanical and biochemical injury. These findings shed light on the physiological mechanisms controlling Treg and might open the way to novel therapeutic strategies for downregulating Treg activity (e.g., in neuronal degeneration) or for strengthening it (in autoimmune diseases).

Expression of GTP-dependent and GTP-independent Tissue-type Transglutaminase in Cytokine-treated Rat Brain Astrocytes

Tissue-type transglutaminases (TGases) were recently shown to exert dual enzymatic activities; they catalyze the posttranslational modification of proteins by transamidation, and they also act as guanosine triphosphatase (GTPase). Here we show that a tissue-type TGase is expressed in rat brain astrocytes in vitro, and is induced by the inflammation-associated cytokines interleukin-1β and to a lesser extent by tumor necrosis factor-α. Induction is accompanied by overexpression and appearance of an additional shorter clone, which does not contain the long 3′-untranslated region and encodes for a novel TGase enzyme whose C terminus lacks a site that affects the enzymes interaction with guanosine triphosphate (GTP). Expression of two clones revealed that the long form is inhibited noncompetitively by GTP, but the short form significantly less so. The different affinities for GTP may account for the difference in physiological function between these two enzymes.

Developmental expression of the VIP-gene in brain and intestine

Abstract Vasoactive intestinal peptide (VIP) is a major regulatory peptide in the nervous system, playing a role in normal brain activity. VIP levels change dramatically during postnatal rat brain development, raising the question of how these changes are regulated. To study VIP-gene expression, a sensitive RNA detection assay which uses in vitro-transcribed RNA hybridization probes, corresponding to 4 exons of the VIP-gene, was adapted. Results show that the major VIP-mRNA was 2000–2100 bases long in the rat. The amounts of this RNA varied markedly with development. In the frontal cortex of the rat brain, the 2000–2100-base mRNA increased by at least 5-fold from birth to 3–4 days, showing a maximal content at 14–16 days. VIP-mRNA synthesis therefore apparently precedes peptide synthesis by several days, as VIP in the rat cortex begins to increase only at about 7 days of age. Similarly, in the parietal cortex, VIP-mRNA was detected by 3 days of age. However, the increase in the mRNA content from 3 to 14 days of age was greater than in the frontal cortex, while almost no VIP-mRNA was detected in the newborn rat parietal cortex. In contrast, the hypothalamus and intestine contained significant quantities of VIP-mRNA at birth, the hypothalamic levels in newborns being much higher than anticipated from the peptide levels. In the hippocampus, the major peak in VIP-mRNA content occurred at 8 days of age. Taken together, these results indicate local controls of VIP-gene expression and a developmentally associated role for VIP-gene products. As the VIP-mRNA levels did not always parallel the peptide levels, regulation at the post-transcriptional stage may be essential for normal VIP function.

Vasoactive Intestinal Peptide Gene Expression from Embryos to Aging Rats

Vasoactive intestinal peptide (VIP) gene transcripts were demonstrated by RNA blot hybridization using VIP-specific RNA hybridization probes. High levels of expression were observed as early as in 16-day-old embryos. In aging rats, the VIP-mRNA levels were reduced significantly (in the cerebral cortex) as compared to 21-day-old rats. Our results suggest a role for the VIP gene protein products during embryonal development. During aging processes the decrease in VIP gene transcripts may be a consequence of either a reduction in the transcriptional activity of VIP neurons or death of VIP-producing cells.

Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus

The participation of gonadal steroid hormones in regulation of the vasoactive intestinal peptide (VIP) gene expression in the hypothalamus was studied using a quantitative densitometric hybridization assay. In the female rat the levels of VIP mRNA were found to be significantly decreased following ovariectomy (4.41 ± 0.7 arbitrary units of absorbance vs. 8.52 ± 0.18). This decrease was largely reversed after three days of treatment with estradiol dibenzoate. In contrast to the female rats, no significant change in VIP mRNA levels was observed in the male rats, following orchidectomy. These results suggest a sexual dimorphism with regard to the steroid regulation of hypothalamic VIP gene expression in the rat.

Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor

To identify the VIP biosynthetic pathways, we have isolated the human VIP gene, using synthetic oligodeoxynucleotides. These specific hybridization probes were constructed according to the neuroblastoma VIP-cDNA sequence and contained up to 39 bases. The gene structure was deduced by direct chemical nucleotide sequencing. Six exons were thus far discovered; among them two short exons, one encoding VIP and the second encoding PHM-27 (a peptide having a N-terminal histidine and C-terminal methionine amide, closely related in sequence and activity to VIP). As a model system for VIP gene expression, we used a human buccal tumor producing elevated amounts of VIP. In these cells, a major transcript of the VIP-gene was identified as a long RNA containing intron sequences. The occurrence of elevated quantities of a high molecular weight, intron containing, gene transcript which is not processed directly into mature RNA suggests that VIP gene expression may be regulated at the RNA processing level.

Self-Protective Mechanism Awakened by Glutamate in Retinal Ganglion Cells

The progression of degeneration in chronic optic neuropathies or in animal models of optic nerve injury is thought to be caused, at least in part, by an increase in glutamate to abnormally high concentrations. We show here that glutamate, when injected in subtoxic amounts into the vitreal body of the rat eye, transduces a self-protecting signal that renders the retinal ganglion cells resistant to further toxicity, whether glutamate-derived or not. This neuroprotective effect is attained within 24 h and lasts at least 4 days. Western blot analysis of rat retinas revealed increased amounts of bcl-2 four days after injection of glutamate in either subtoxic or toxic (120 nmol) amounts, but not after saline injection. The effects of intravitreal glutamate or saline injection on the secretion of neurotrophins by retinal ganglion cells was evaluated in rat aqueous humor 6 h, 1 day, and 4 days after injection. Nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 showed similar kinetic patterns in all of the eyes; that is, they increased to a peak 1 day after the injection and returned to normal by day 4. However, increased amounts the neurotrophin receptor TrkA within the retinal ganglion cell layer and nerve fiber layer were detected 1 day after injection of glutamate in either toxic or subtoxic amounts, but not after saline injection. This finding points to the possible involvement of neurotrophin receptors in regulation of the cellular responses to glutamate challenge. Identification of the intracellular signals that trigger the glutamate-induced self-protective mechanism would shed light on the genetic balance needed for survival, and guide the development of drugs for the up-regulation of desired genes and their products.

Adrenalectomy decreases vasoactive intestinal peptide mRNA levels in the rat suprachiasmatic nucleus

Vasoactive intestinal peptide (VIP) concentrations were shown to be regulated by adrenal steroids. Therefore, we investigated whether adrenal steroids affect VIP mRNA levels, which would suggest an effect on VIP mRNA expression. Adrenalectomy performed on adult male rats resulted in a significant decrease in VIP mRNA in the hypothalamus (from 10.6 +/- 0.3 to 3.5 +/- 0.2 arbitrary units). In situ hybridization experiments revealed that a major site of VIP mRNA expression in the hypothalamus is the suprachiasmatic nucleus. Indeed, adrenalectomy resulted in an approximate decrease by half in VIP transcripts in this nucleus. However, this decrease was not reversed by replacement treatment with corticosterone or the glucocorticoid agonist, RU28362. Thus, VIP mRNA may be regulated by indirect mechanisms, influenced by the adrenal gland.

Studies toward the biosynthesis of vasoactive intestinal peptide (VIP)

In view of the potential biological importance of VIP, we have begun to examine the regulation of its biosynthesis. For this purpose we have, as a first step, searched for an enriched source of VIP biosynthesis. By a combination of chromatographic procedures and radioimmunoassays we discovered an as yet unknown source for VIP production, namely a human buccal tumor, containing 0.67 +/- 0.05 ng VIP/micrograms protein which is greater than the richest source in brain (the cerebral cortex). Thus, we decided to use the tumor tissue for VIP-mRNA purification and characterization. To identify VIP-mRNA we are using as hybridization probes, synthetic oligodeoxynucleotides with relatively unambiguous nucleotide sequence complementary to the predicted VIP-mRNA sequence. These probes are synthesized, using the deoxynucleoside phosphoramidite approach, to a length of 17 bases each, and contain all the possible DNA sequences according to the genetic code. These specific probes are then radioactively labelled using the reaction catalyzed by the enzyme polynucleotide kinase and afterwards hybridized to mRNA, which had been resolved on denaturing agarose gels. Employing this approach, we identified a single putative VIP-mRNA band which was then partially purified by sucrose gradient centrifugation. Upon in vitro translation in a rabbit reticulocyte lysate cell free system, this mRNA was found to code for VIP immunoreactive proteins. In conclusion, our studies suggest the existence of high molecular weight precursors to VIP cross-reactive with anti-VIP antibodies, that are coded for by a partially purified mRNA containing VIP sequences.